September 16, 2015

The Honorable Orrin G. Hatch
Chairman
Committee on Finance
United States Senate
Washington, DC 20510

The Honorable Ron Wyden
Ranking Member
Committee on Finance
United States Senate
Washington, DC 20510

Dear Chairman Hatch and Ranking Member Wyden:

On behalf of dozens of organizations on the front line of our nation’s prescription opioid and heroin crisis and on behalf of hundreds of thousands of American families devastated by opioid addiction, we are writing to you about a Senate Finance Committee investigation launched in 2012. We respectfully request that you make public the findings from this investigation.

On May 8, 2012, Senators Grassley and Baucus sent letters to three opioid manufacturers and seven non-profit organizations that have promoted aggressive opioid use. In their letters to these groups, they wrote:

“There is growing evidence that pharmaceutical companies that manufacture and market opioids may be responsible, at least in part, for this epidemic by promoting misleading information about the drugs’ safety and effectiveness.”

The Senate Finance Committee investigation sought information on efforts by opioid makers and nonprofit groups to encourage aggressive opioid prescribing for common conditions like low back pain, where risks of use outweigh benefits. These efforts led to a sharp increase in opioid prescriptions and consequently to soaring rates of addiction, overdose deaths, infants born opioid-dependent, and other health and social problems. According to the CDC, overexposure of our population to opioid painkillers has also led to a new heroin problem.

Opioid overdoses, once rare in the United States, have caused more than 220,000 deaths (175,000 from painkillers and 45,000 from heroin) since 1999. That is more than double the number of American lives lost in Vietnam, Iraq and Afghanistan combined. In other words, the efforts by opioid manufacturers to increase opioid prescribing have led to a public health catastrophe that may take decades for our country to recover from.
Senate Finance Committee staff spent several months collecting and sorting through the
records they requested. Regrettably, the findings from this investigation have never been
shared with the public. This is why we are writing to you.

The results of the investigation are not simply a matter of historical importance. Some of
these same companies and non-profit groups have continued to promote aggressive opioid
use and continue to block federal and state interventions that could reduce
overprescribing. In addition, some of the individuals mentioned in the Committee’s letters
to drug companies continue to work as advisors to federal agencies, including the Food and
Drug Administration and the National Institutes of Health.

To bring our nation’s epidemic of opioid addiction to an end, we must reduce
overprescribing of opioids. This goal will be difficult to achieve if opioid makers, and the
groups they fund, continue to promote aggressive and inappropriate prescribing. We urge
you to release the findings from the Committee’s investigation of their activities.

Sincerely,

G. Caleb Alexander, MD, FACP
Co-Director, Johns Hopkins Center for Drug Safety and
Effectiveness
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD

Samuel A. Ball, PhD
President and CEO
CASA Columbia®
New York, NY

Jane Ballantyne M.D., F.R.C.A.
President
Physicians for Responsible Opioid Prescribing (PROP)
New York, NY

Betty Blackburn
Director of Community Relations
American Addiction Centers
Brentwood, TN

Marianne Burke, Ph.D.
State Director, Virginia C.A.N.
(Change Addiction Now)
Fairfax, VA

Daniel A. Busch, MD
Northwestern University, Feinberg School of Medicine
Founder, StopDrugDeath.com
Evanston, IL
Danesh Mazloomdoost, MD
Founder
Pain Management Medicine
Lexington, KY

Janis McGrory
Founder
Lower Cape Community Anti-Drug Network
Cape Cod, MA

Joanne Peterson
Founder and Executive Director
Learn2Cope
Boston, MA

April J. Rovero
President
National Coalition Against Prescription Drug Abuse (NCAPDA)
San Ramon, CA

Judy Rummler
President
Steve Rummler Hope Foundation
Minneapolis, MN

Marvin D. Seppala, MD
Chief Medical Officer
Hazelden Betty Ford Foundation
Center City, MN

Raymond V. Tamasi
President and CEO
Gosnold on Cape Cod
Falmouth, MA

Carol McDaid
Co-Founder
McShin Foundation
Richmond, VA

Michele McTiernan-Gleason
Director of Recovery Wellness
Connect the Pieces to Prevent Prescription Drug Abuse
Boise, ID

Mel Pohl, MD
Medical Director
Las Vegas Recovery Center
Las Vegas, NV

Sherrie Rubin
Director
The Hope2gether Foundation
San Diego, CA

Susan Salomone
Founder
Drug Crisis in our Backyard
Mahopac, NY

Jean Silver-Isenstadt, MD, PhD
Executive Director
National Physicians Alliance
Washington, DC

Ken Thompson, MD
Trusted Servant
Like Minded Docs
Strasburg, PA
Duana Wilkins
Executive Director
Change Addiction Now, United We C.A.N.
Mount Vernon, WA

William H. Williams
Co-Founder
Where There’s A Will Fund
New York, NY